GM-2505 explained

GM-2505 is a psychedelic and experimental antidepressant that acts as a 5-HT2A and 5-HT2C receptor agonist and serotonin releasing agent.[1] [2] [3] Compared to other 5-HT2A receptor agonists, it is said to have a shorter duration of action.[3] [4] It is under development by Gilgamesh Pharmaceuticals. As of March 2024, GM-2505 is in phase 2 clinical trials for the treatment of major depressive disorder. The chemical structure of GM-2505 does not yet seem to have been disclosed, but disclosed compounds with the same mechanism of action have been patented by Gilgamesh in 2022.[5]

Notes and References

  1. Web site: GM 2505 . AdisInsight . 22 March 2024 . 30 August 2024.
  2. Witkin JM, Golani LK, Smith JL . Clinical pharmacological innovation in the treatment of depression . Expert Rev Clin Pharmacol . 16 . 4 . 349–362 . April 2023 . 37000975 . 10.1080/17512433.2023.2198703 . GM-2505 is a dual-acting compound with both agonist activity at 5-HT 2A receptors and a releaser of 5-HT. [...].
  3. Conference-poster: Hughes . Zoe . Klein . Adam . Dvorak . Dino . Austin . Eric . Kiss . Laszlo . Marek . Gerard . Sporn . Jonathan . Kruegel . Andrew . 22. GM-2505 has Rapid Onset Antidepressant Activity and Causes Dose-Dependent Changes in qEEG With Increasing 5-HT2A Receptor Occupancy . Biological Psychiatry . 93 . 9 . 2023 . 10.1016/j.biopsych.2023.02.262 . S102–S103.
  4. News: Beaney . Abigail . Gilgamesh to initiate Phase IIa trial of fast-acting psychedelic drug . 7 December 2023 . Clinical Trials Arena . 6 December 2023.
  5. Web site: Methods of treating mood disorders . Google Patents . 2022 . 14 November 2024.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "GM-2505".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.